Call Options

13 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $209,525 - $247,500
-2,500 Reduced 11.68%
18,900 $1.65 Million
Q4 2023

Feb 13, 2024

BUY
$76.22 - $98.51 $1.63 Million - $2.11 Million
21,400 New
21,400 $2.06 Million
Q2 2023

Aug 11, 2023

SELL
$86.68 - $100.3 $9.54 Million - $11 Million
-110,100 Reduced 89.59%
12,800 $1.11 Million
Q1 2023

May 12, 2023

BUY
$87.74 - $117.27 $10.8 Million - $14.4 Million
122,900 New
122,900 $12 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $1.53 Million - $1.8 Million
18,600 New
18,600 $1.58 Million
Q2 2021

Aug 13, 2021

BUY
$75.51 - $84.79 $679,590 - $763,110
9,000 Added 31.14%
37,900 $3.16 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $1.76 Million - $2.14 Million
-23,600 Reduced 44.95%
28,900 $2.18 Million
Q4 2020

Feb 12, 2021

SELL
$72.61 - $90.2 $907,625 - $1.13 Million
-12,500 Reduced 19.23%
52,500 $4.6 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $3.23 Million - $5.9 Million
45,000 Added 225.0%
65,000 $4.95 Million
Q2 2020

Aug 14, 2020

BUY
$79.55 - $124.22 $1.42 Million - $2.21 Million
17,800 Added 809.09%
20,000 $2.47 Million
Q2 2019

Aug 14, 2019

SELL
$80.35 - $93.9 $2.11 Million - $2.47 Million
-26,300 Reduced 92.28%
2,200 $188,000
Q1 2019

May 15, 2019

BUY
$84.2 - $98.62 $2.25 Million - $2.63 Million
26,700 Added 1483.33%
28,500 $2.53 Million
Q3 2018

Nov 13, 2018

BUY
$93.92 - $105.72 $169,056 - $190,296
1,800 New
1,800 $175,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.